대한핵의학회지 (The Korean Journal of Nuclear Medicine)

대한핵의학회 (The Korean Society of Nuclear Medicine)
권호 표지

신경계 퇴행성 질환에서의 도파민 운반체 영상

Dopamine Transporter Imaging in Neurodegenerative Disorders

  • 김재우 (동아대학교 의과대학 신경과학교실)
  • Kim, Jae-Woo (Department of Neurology, Dong-A University College of Medicine)
  • 발행 : 2003.02.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The dopamine transporter (DAT) is responsible for the re-uptake of dopamine from the synaptic cleft and is located on dopaminergic nerve terminals only. DAT single photon emission computed tomography (SPECT) and positron omission tomography (PET) imaging, therefore, offer the unique opportunity to study via striatal uptake the integrity of presynaptic dopaminergic nerve terminals in vivo. In recent years SPECT and PET using specific ligands binding to DAT have evolved as an useful tool for diagnosing and monitoring progression of neurodegenerative disorders affecting dopaminergic systems. This article briefly reviews the literature dealing with DAT SPECT and PET imaging in parkinsonism and other neurodegenerative disorders.

키워드

참고문헌

  1. Kuhar MJ, Sanchez-Roo PM. Dopamine Transporter: Biochemistry, Pharmacology and Imaging. Eur Neurol 1990;30(suppl 1):15-20
  2. Kim JW, Kim Y, Baek SY. Densities of dopamine transporter in MPTP-treated mice model for Parkinson's disease. J Korean Neural Assoc 2002;21(suppl 2):175
  3. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SR, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in Parkinson's disease. Ann Neural 1993;34:423-31
  4. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, et al, Decreased single photon emission computed tomographic [123I]$\beta$-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98
  5. Marek KL, Seibyl JP. A molecular map for neurodegeneration. Science 2000;289(5478) :409-11
  6. Kugaya A, Fujita M, Innis RB. Application of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders. Ann Nucl Med 2000;14:1-9
  7. Neumeyer JL, Wang S, Milius RA. [123I]-2-$\beta$ -Carbomethoxy-3$\beta$-(4-iodophenyl)- tropane: high affinity SPECT radiotracer of monoamine uptake sites in brain. J Med Chem 1991;34:3144-6
  8. Abi-Dargham A, Gandelman MS, DeErasquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of $\beta$-CIT. J Nucl Med 1996;37:1129-33
  9. Rinne JO, Kuikka IT, Bergstrom KA, Rinne UK. Striatal dopamine transporter in different disability stages of Parkinson's disease studied with [123I]$\beta$-CIT SPECT. Parkinsonism and Related Disorders 1995;1:47-51
  10. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-64
  11. Donnan GA, Woodhouse DG, Kaczmarczyk SJ. Evidence for plasticity of the dopaminergic system in parkinsonism. Mol Neurobiol 1991;5:421-33
  12. Ilgin N, Zubieta J, Reich SG, Dannals RF, Ravert HT, Frost n. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease. Neurology 1999;52:1221-6
  13. Innis RB, Seibyl JP, Scanley BE. single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-69
  14. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002;17:45-53
  15. Seibyl J, Marek KL, Sheff K, Innis RB. [123I]beta-CIT brain SPECT imaging of dopamine transporters in Parkinson's disease and Parkinson syndrome. J Nucl Med 1996;37: 134p
  16. Brucke T, Asenbaum S, Pirker W. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I]beta-CIT and SPECT. J Neural Transm Suppl 1997; 50:9-24
  17. Tatsch K. Imaging of the dopaminergic system in parkinsonism with SPET. Nucl Med Communicatios 2001;22:819-27
  18. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [123I]beta-CIT SPEer imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1023-32
  19. Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B. [1231] beta-CIT SPECT imaging demonstrates bilateral loss of dopamine transporter in hemi-Parkinson's disease. Neurology 1996;46:231-7
  20. Marek KL, Seibyl JP, Fussel B, Cellar J, Smith E, Innis R, et al. [123I]beta-CIT: assessment of progression in Parkinson's disease. Neurology 1997;48(suppl):A207-8
  21. Booij J, Winogrodzka A, Bergmans P, Wolters EC, Stoof JC, Royen EA, et al. [123I]beta -CIT and [123I]FP-CIT SPECT are useful methods to monitor progression of dopaminergic degeneration in early-stage Parkinson's disease. J Nucl Med 1999;40: 28p
  22. Nurmi E, Ruottinen HM, Kaasinen V. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 2000;47:804-8
  23. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 2002;287: 1653-61
  24. Brooks DJ, Ibanez V, Sawle GV. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration and progressive supranuclear palsy measured with llC-raclopride and positron emission tomography. Ann Neurol 1992; 31:184-92
  25. von Royen EA, Verhoeff NPLG, Speelman JD, Wolters EC, Kuiper MA, Janssen AGM, et al. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol 1993;50:513-6
  26. Kim Y, Kim JM, Kim JW, Yoo CI, Lee CR, Lee JH, et al. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what dose it mean? Mov Disord 2002; 17:568-75
  27. Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, et al. Dopamine transporter density measured by [123I]$\beta$-CIT single photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998;43:792-800
  28. Messa C, Volonte M, Fazio F. Differential distribution of striatal [123I]$\beta$-CIT in Parkinson's disease and progressive supranuclear palsy evaluated with single photon emission computed tomography. Eur J Nucl Med 1998;25:1270-6
  29. Kim IW, Kim Y, Cheong HK, Kengo Ito. Manganese induced parkinsonism. J Korean Med Sci 1998;13:437-9
  30. Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutation in the GTP cyclohydrolase 1 gene. Nat Genet 1994;8:236-42
  31. McKeith IG. Dementia with Lewy bodies. British J Psychiatry 2002;180:144-7
  32. Park MI, Kang DY, Park KW, Kim IW. Parkinsonism in dementia with Lewy bodies: comparison with Parkinson's disease. J Korean Neurol Assoc 2002;21(supl.2): 214
  33. Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease. Eur J Nucl Med 2001;28:1523-8
  34. Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134-40
  35. Molsa PK, Marttila RI, Rinne UK. Extrapyramidal signs in Alzheimer's disease. Neurology 1984;34: 1114-6
  36. Lavalaye J, Booij J, Reneman L. Effect of age gender on dopamine transporter imaging with [123I]FP-CIT SPECT in healthy volunteers. Eur J Nucl Med 2000;27:867-9
  37. van Dyck CH, Seibyl IP, Malison RT, Lauelle M, Wallace E, Zoghbi 55, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-$\beta$CIT SPECT. J Nucl Med 1995;36:1175-81